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Abstract
Background: The language of “participant-driven research,” “crowdsourcing” and “citizen science” is increasingly
being used to encourage the public to become involved in research ventures as both subjects and scientists.
Originally, these labels were invoked by volunteer research efforts propelled by amateurs outside of traditional
research institutions and aimed at appealing to those looking for more “democratic,” “patient-centric,” or “lay”
alternatives to the professional science establishment. As mainstream translational biomedical research requires
increasingly larger participant pools, however, corporate, academic and governmental research programs are
embracing this populist rhetoric to encourage wider public participation.
Discussion: We examine the ethical and social implications of this recruitment strategy. We begin by surveying
examples of “citizen science” outside of biomedicine, as paradigmatic of the aspirations this democratizing rhetoric
was originally meant to embody. Next, we discuss the ways these aspirations become articulated in the biomedical
context, with a view to drawing out the multiple and potentially conflicting meanings of “public engagement”
when citizens are also the subjects of the science. We then illustrate two uses of public engagement rhetoric to
gain public support for national biomedical research efforts: its post-hoc use in the “care.data” project of the
National Health Service in England, and its proactive uses in the “Precision Medicine Initiative” of the United States
White House. These examples will serve as the basis for a normative analysis, discussing the potential ethical and
social ramifications of this rhetoric.
Summary: We pay particular attention to the implications of government strategies that cultivate the idea that
members of the public have a civic duty to participate in government-sponsored research initiatives. We argue that
such initiatives should draw from policy frameworks that support normative analysis of the role of citizenry. And,
we conclude it is imperative to make visible and clear the full spectrum of meanings of “citizen science,” the
contexts in which it is used, and its demands with respect to participation, engagement, and governance.
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Background: public roles in science
The promise of emerging scientific capacities to distill use-
ful knowledge from “big data” is leading the scientific com-
munity to seek out more efficient ways to gather large
numbers of empirical observations for analysis. For human
health research, this means gathering more data about
more humans. Nationally sponsored health research initia-
tives, like the “care.data” project in England or the “Preci-
sion Medicine Initiative” in the United States (US), wish to
develop ways to enlist more members of the public to
support this research need. In this paper, we explore strat-
egies that contemporary national research initiatives are
employing to encourage public cooperation and their eth-
ical and social implications.
Members of the public become involved with scientific
research in three distinct, if overlapping, ways. First, when
the research is about some feature of their lives, the people’s
role is to provide the data under study. Traditionally we de-
scribe this role as being human “subjects,” but today we
often call it research participation. “Participation” suggests
an active, intentional role, but can also describe quite
passive forms of inclusion. People usually consent to
participation in research about themselves; however, with
proper safeguards and democratic approvals, the public
might even be included in studies without their knowledge.
Second, a common way to describe the public’s awareness
and understanding of their participation, in turn, is in terms
of their engagement with the research. Members of the
public can be more or less engaged in scientific studies, de-
pending on the extent to which scientists seek to communi-
cate their plans and solicit the public’s cooperation in
collecting data. In this sense, the public can be more or less
‘engaged’ with research whether or not they ‘participate’ in
it because engagement is independent of their inclusion as
research subjects. Third, in some cases, members of the
public have an active role in in the planning and conduct of
the research itself, even to the level of choosing the scien-
tific questions to be addressed [1]. The UK National Health
Service’s INVOLVE agency uses the term “involvement” to
label this more active public role. A Venn diagram, which
we present in Fig. 1, is a useful way to depict the overlap
between the three concepts of “participation,” “engage-
ment,” and “involvement,” [2].
At one level, the needs that national health research ini-
tiatives have for data about large numbers of people create
a demand for more public participation. But unless the sci-
entific community can justify involuntarily imposing such
initiatives on the public, participation requires citizens to
cooperate in making data about themselves available.
“Engagement” and “involvement” practices are both ways
to cultivate that cooperation by building public trust and a
sense of collective investment in research. We are inter-
ested in the ways national health research initiatives invoke
both types of practices in their promotional rhetoric and, in
particular, their appeals to more active forms of citizen in-
volvement in scientific governance. Specifically, we are in-
terested in the ways these terms intersect with yet another
term, “citizen science.” The citizen science movement of
the last three decades has been a paradigm for active public
involvement in science outside of health research. Recently,
it has increasingly been used in health research as well. As
“citizen science’ language penetrates more deeply into bio-
medical research, it raises questions about how “participa-
tion” should be interpreted, what normative factors are
entailed by a given interpretation, and what this says
about the rights, duties, and overall role of a citizen in
biomedical research as various visions of societal good
are pursued.
In this paper, we explore strategies that contemporary
national research initiatives are employing to encourage
public cooperation and their ethical and social implications.
We begin with an analysis of the mixed uses of “participa-
tion,” “engagement,” and “involvement,” and how they
pertain to “citizen science,” to bring normative questions
surrounding this language to the fore. “Citizen science” of-
fers a good starting place for our analysis, since the scien-
tific appeal of its aspirations is relatively transparent. Below,
we discuss a number of “citizen science” initiatives to dem-
onstrate the wide range of efforts which employ the term.
Next, we discuss the ways these aspirations become articu-
lated in the biomedical context, with a view to drawing out
the multiple and potentially conflicting meanings of “public
engagement” when citizens are actually the subjects of the
science. We then illustrate two uses of public engagement
rhetoric to gain public support for national biomedical re-
search efforts: its post-hoc use in the UK with the National
Health Service (NHS) “care.data” project and its proactive
use in the US White House “Precision Medicine Initiative.”
These sections of our paper will then serve as the basis for
a normative analysis, in which we probe the potential eth-
ical and social ramifications of governmental use of this
rhetoric to encourage participation in biomedical research.
To foreshadow our conclusion, the ironic risk of this strat-
egy may be that stronger public engagement rhetoric might
be used to bolster a sense of civic duty to participate in
national research initiatives, even when their benefits
flow as much to the private sector as to public welfare.
Looking ahead, new understandings of the social con-
tract between science, government and the public may
be required to address these health research risks to
civil liberties.
The growth and appeal of “citizen science”
“Citizen science” has become an umbrella term that ap-
plies to a wide range of activities that involve the public in
science. It was coined independently by Rick Bonney in
the US and Alan Irwin in the UK in the mid-1990s [3].
Bonney understood it primarily as a strategy for building
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public scientific literacy and trust, in which scientists and
scientific institutions would take the “top-down” initiative
to expose laypeople to the processes of scientific research
in ways designed to cultivate their enthusiasm and sup-
port, [3] fitting in the public “engagement” category of
Fig. 1. At a minimum, this could include educational ef-
forts to increase public understanding and enthusiasm for
science. However, the label could also apply to research
projects enlisting large numbers of volunteer “amateur
scientists” in the collection and reporting of data on fac-
tors in their surrounding environments. The citizens’ role,
as volunteer data collection assistants, would be to con-
tribute empirical observations for analysis by professional
scientists. Under this interpretation, “citizen science” pro-
jects have been mounted toward wide-ranging objecti-
ves—from bird migration patterns and ecological trends
to the identification of food security factors that act as
early warning indicators for famine [4]. Beyond that, sci-
entists also have begun to solicit the public’s help in data
analysis—or at least in computer time—from NASA mis-
sion data to folding proteins and running large calcula-
tions [5]. At this level, the citizens might even claim to be
“involved” in the conduct of science, albeit only as a lender
of hardware and processing power. In all these cases, the
goal is to propel science within the constraints of its trad-
itional institutional contexts, and under the supervision of
professional scientists [6].
By contrast, Irwin’s “bottom up” construction of citizen
science is more policy directed, and describes practices
more squarely in the “involvement” category of Fig. 1. For
Irwin, “citizen science” has the goal of emancipating the
pursuit of science from its traditional institutional and pro-
fessional setting [7]. Under this interpretation, community-
based urban planning or environmental science projects
Fig. 1 A useful way to depict the overlap between the three concepts of “participation,” “engagement,” and “involvement”
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that are responsive to community needs and involve lay
people in the conduct and governance of research are the
exemplars of “citizen science.” These include lay environ-
mental justice projects to examine the consequences of the
Chernobyl nuclear accident [8] and Hurricane Katrina in
Louisiana [9, 10]. At the extreme, lay people have begun
using “crowdsourcing” and other techniques to conceive
and conduct their own research projects outside of the
traditional scientific community altogether [11].
When viewed through a normative lens, we see that Irwin
and Bonney propose two different ways to advance the
good of society. Bonney’s vision is based upon the pre-
sumed benefits of scientific knowledge in its own right.
Irwin’s, in contrast, is based upon presumed emancipatory
benefits of active public input on the direction of scientific
research agendas. Bonney and Irwin’s two versions of “citi-
zen science” are not necessarily mutually exclusive, but the
difference in their orientation is reflected in the spectrum
of initiatives with different objectives that have adopted the
label, from projects that simply strive for public transpar-
ency to those that seek to put laypeople at the scientific
controls. In any given initiative, the two visions of societal
good may be aligned with one another. But when they do
not align, it points to a fault line running through the
conceptualization of the term “citizen science” itself—with
contrasting visions of what constitutes societal good
employing the same term to describe themselves. These dif-
fering visons for the role of scientific research in society call
attention to the complex relationships between science,
public goods, societal good, and public participation. They
raise a key question: How much public input should go into
deciding which vision of societal good a government should
pursue?
The simple distinction drawn between Bonney and
Irwin’s conceptualizations of citizen science highlights dif-
ferences in how involving citizens in scientific research can
advance societal good. When we look to the range of initia-
tives currently being described as “citizen science,” the pic-
ture gets much more complicated. Barbara Prainsack
identifies nineteen parameters organised under six categor-
ies which allow for a much more granular and intricate un-
derstanding and classification of citizen science projects.
This typology reveals just how complex and multifarious
proposed relationships between science, public goods, soci-
etal good, and public participation can become [12].
Prainsack’s primary objective is to question whether or
not citizen science changes how we assess expertise and
authority in creating scientific knowledge, and how it does
or should support participation in science. Yet a related
aim is to determine whether and how citizen science
makes science more socially robust by corresponding with
dominant social, political, ecological, and commonly
shared values. Or, if it makes science better in other ways,
she asks, who benefits? [12]. Therefore, her typology could
also be applied to help determine whether or not citizen
science marks a change in how we assess expertise and
authority in determining what vision for a better society to
pursue, and how to best realise it given the complex inter-
relations discussed above. When seen in this way, Prain-
sack’s typology underscores just how many different
conceptions of “societal good” could potentially be under-
lying citizen science initiatives.
However, despite these differences, across the spectrum,
almost all citizen science initiatives share three features
that make its rhetoric particularly appealing to apply to
large population-based biomedical research projects: (1)
connections to the spreading popularity of personal infor-
mation communication technologies (ICTs); (2) “crowd-
sourced” problem-solving; and (3) the “grass-roots”
fundraising strategies that they facilitate.
First, the recent explosion of citizen science initiatives
can largely be attributed to the integration of ICT into
everyday life through computers, smartphones, the inter-
net, and social media. This new potential for data collec-
tion provided by ICT is expanding opportunities for lay
volunteers to collect, supply, and analyze information for
data intensive research projects. Depending on the pro-
ject, scores, hundreds, or thousands of volunteers can
potentially provide millions of data points per month,
[4] resulting in big data sets whose scientific significance
is subsequently determined by experts and, in some
cases, enhanced through statistical tools and techniques
that facilitate analysis of complex data [13]. Citizen sci-
ence is touted as a way to tackle otherwise intractable,
laborious, and potentially costly research problems. Cap-
able of coordinating the efforts of millions of lay people
around the globe, it is said to allow researchers to think
about data collection on a population-wide scale.
Second, the term “citizen science” is commonly used to
not only refer to data collection, but also access to un-
tapped resources that individual citizens can provide
through ICT for data processing, interpretation, and prob-
lem solving. These “distributed intelligence” methods are
said to offer scientists with low-cost options for data pro-
cessing that could otherwise pose formidable barriers to
research. A wide range of online interfaces and programs
offered through, for instance, Zooniverse, [14] allow lay-
people to assist with interpreting scientific datasets. These
may provide images to the public in need of classification,
ranging from galaxies (Einstein@home) [15] to tumour re-
search (Cell Slider) [16]. Or, as with a Facebook-based
game called Fraxinus, [17] they may be designed to allow
the public to assist with sequence alignment in compara-
tive genomics and pathogen genomics [18]. Or, as with
Foldit, [19] they may be designed to enable the public to
help determine the folding structure of proteins. In cases
like these, “citizen science” becomes associated with vari-
ous forms of technology-mediated social participation
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(TMSP), [20] where the level of participant engagement
can vary from the passive loaning of a computers’ process-
ing power, to a video game-based interface where there is
little to no connection to the science, to an interface that
requires genuine understanding of scientific principles. Al-
though paradigms of crowdsourcing like Wikipedia are
defined by the power of collective problem-solving, the lit-
erature that equates citizen science and crowdsourcing
tends to present scenarios where citizens are only pas-
sively involved, having less to do with engaged citizenry or
scientific literacy than with offering latent resources
which, in one way or another, could advance a research
agenda [21].
Finally, “citizen science” has been used in reference to
fundraising for science, both philanthropically and politic-
ally. This usage also has a very high degree of overlap with
crowdsourcing literature, in which citizen science is pro-
moted as a means to improve funding applications through
its ability to increase the impact of research by having an
effect on the lay public. But more than this, there are also
arguments for funding scientific research by petitioning in-
dividuals for financial support. Here, scientific research is
presented less as a societal good and more as a way to pro-
vide products to potential investors. Citizen science initia-
tives are cast in terms of “excellent strategic investments
for both private and government foundations,” as “critical
for increasing public support,” and as something that can
“open both pocketbooks and minds.” [22]. This presents
scenarios where scientific goals, education goals, and finan-
cial goals vie for priority. There is a blurring of the distinc-
tion between educating the public about the value of
science and “a sales pitch aimed at the public” in the mar-
keting of a particular research agenda in that “[t]oday’s in-
vestors could become tomorrow’s advocates for scientific
research,” [22]. This invites conjecture about the use of co-
ercive lures, whether wealthy donors might expect special
treatment, and whether research objectives might ultim-
ately be correlated to financial generosity of certain individ-
uals or groups over others [23].
The three core features of citizen science—leveraging of
widely distributed ICT, harnessing the “collective wisdom”
of the populace, and cultivating enthusiasm and support for
science—make it very attractive to governments interested
in propelling labor and data-intensive research in a cost ef-
ficient manner. For example, in the US, the Obama Admin-
istration’s 2013 Second Open Government National Action
Plan [24] includes a “call to action” “for federal agencies to
harness the ingenuity of the public by accelerating and
scaling the use of open innovation methods such as citizen
science and crowdsourcing in a variety of national priority
areas,” [25] producing a wide variety of federally sponsored
“citizen science” research programs under an overarching
inter-agency “Community of Practice” initiative that seeks
to “expand and improve the US government’s use of
crowdsourcing, citizen science and similar public participa-
tion techniques for the purpose of enhancing agency mis-
sion, scientific, and societal outcomes,” [26]. These
governmental initiatives lead to our focal question: What
does “citizenship” have to do with “citizen science”? Two
specific governmental initiatives, which we take up in sec-
tion 3, are particularly instructive case studies: the English
“care.data” project and the US “Precision Medicine
Initiative.”
Citizen science and biomedical research: creating a
language of confusion
The vast majority of biomedical research takes place in
the “participatory” sphere, where humans are the primary
source of data gathered (whether those data are biometric,
genetic, demographic, behavioral, etc.) without being “en-
gaged” or “involved” beyond informed consent. However,
recently there has been a turn to inflecting biomedical re-
search (at least rhetorically) with “citizen science” aspira-
tions, like those discussed above, where participants may
have deeper investments in research. The language of in-
volvement and engagement are used to entice and enlist
these human participants to “opt-in” to research. Some
examples of biomedical citizen science research projects
include when patients have been asked to collect data on
environmental factors on human health, monitoring se-
verity of their own symptoms in space and time [27, 28].
Others have been asked to measure the microbes in their
own guts [4]. In the case of the Personal Genome Project,
the term “citizen science” has been used to describe a high
profile genomics initiative where the “citizen’s” role is to
provide the foundational data for any number of research
agendas [23]. Participants agree to allow their genomes to
become publicly available for multiple research objectives
with variable risks. In this context, it has been argued that
the meaning of “citizen science” has morphed to include
community-based participatory research (CBPR), [23] in
which affected communities participate in determining
the scientific issues under study or partake in initiatives
devoted to medical research on issues to which they are
personally connected, such as the Coriell Personalized
Medicine Collaborative. Subsequently, citizen science ter-
minology has been extended to include DNA-related bio-
tech hobbyism and direct-to-consumer genetic testing to
produce a “genomics-informed citizen science” [23] and
other forms of “participant-driven” or “patient-centric”
genomic research [29]. One of the early proponents and
catalytic enterprises to capitalize on citizen science ideolo-
gies was the privately-held, direct-to-consumer genetic
testing company 23andMe.1 While 23andMe’s marketing
focused on providing customers with personalized genetic
information, [30] they also used the genomic and volun-
tary phenotypic data collected for genomic research, most
infamously made evident by the patent they received in
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2012 for polymorphisms associated with Parkinson’s Dis-
ease [31]. The “research” arm of the company, 23andMe,
relied on citizen science and participatory research rhet-
oric, such as exhorting them to “join an effort to translate
basic research into improved health care for everyone” in
order to encourage its customers to become research
“participants.” This included completing optional surveys
about their health status, phenotypic traits, behavioral
habits, and the like that could then be correlated with
polymorphisms for traits of interest.
The aspiration to mobilize members of the public to
conduct or take part in research has been particularly
embraced by patient organizations that have identified a
gap in the research agenda, and have sought to fill it
themselves. Organizations such as Genetic Alliance, [29]
Patientslikeme, [32] and genomera [33] acknowledge the
expertise that patients bring to the research agenda, and
yield considerable benefit from providing a framework
in which patients are able to drive research, in some
cases as an alternative to institution or government-led
research agendas. Within biomedicine, a parallel descrip-
tion of projects can be found in “patient-centric initia-
tives” (PCI) or “patient-driven research” (PDR).
This overlap between PCI/PDR initiatives with other
forms of “citizen science” has been previously recognized
[34]. However, as section 1 demonstrated, the overlap only
occurs at the more populist and proactive end of the
spectrum of interpretations applicable to ‘citizen science.’
For a project to be classed as participant or patient-centric
(or -driven), there is a fundamental requirement for patients
or participants to play significant roles in identifying re-
search priorities and helping to set the research agenda, as a
“bottom up” enterprise in which lay people are not only en-
gaged as learners and assistants, but also as scientists [35].
These terms vary with regard to the specific elements
they encompass, how they fit with the research or health-
care agenda, the interpretation of the researcher or team
applying them, and exactly what they mean for the patient
or participant. For example, the use of the term ‘consumer’
as an alternative to either ‘citizen’ or ‘patient,’ carries a set of
assumptions about the roles of individuals within a market-
driven healthcare or biomedical research setting [36]. Em-
powerment, rights, and responsibilities are recurrent
themes when presenting the implications of terminology
for participation within a research project, with different
terms seemingly selected to emphasize different aspects of
these themes.
This is particularly noteworthy if the primary motivations
for research groups to adopt engagement and involvement
interventions include improving likelihood of funding, and
subsequent recruitment of the required cohort [37]—which
chimes directly with financial opportunity as a priority of
citizen science, as identified in section 1. For instance, it is
often the case that in order to improve participation it is
necessary to engage potential recruits up front and
throughout the research process. Involvement at certain
stages throughout research development and implementa-
tion will also aid participation, by enabling targeted recruit-
ment, and ensuring the research project meets the needs of
its participants. However, in order to involve lay people and
potential participants within this process, it will be neces-
sary to engage with them first. It is for this reason that there
is often confusion about exactly which part of this con-
tinuum is being addressed at any one time, and because en-
gagement is perhaps the easiest and least involved, it is not
unusual for engagement practices to be mistakenly de-
scribed as involvement, to meet a requirement for involve-
ment that has been imposed by a funding body or research
institution.
Although there is confusion over what exactly the terms
“involvement” and “engagement” cover, there are usually
specific motivations for incorporating these elements into
research projects which, in turn, dictate the specific tools
used. Different citizen science projects purport to accom-
modate many of the features of interventions that could be
described more generally as engagement, involvement or
participation. However, the question arises as to whether
the use of the general citizen science rhetoric poses a
greater risk for confusion surrounding the goals of the re-
search project and the expectations of different stake-
holders, including participants, within it.
Case studies
The care.data Project (England)
Confusion over different levels of citizen involvement can
be particularly consequential when the rhetoric and prac-
tices of citizen engagement are used by national science ini-
tiatives to help rebuild public trust and support for projects
that have already run into political trouble. One recent
national biomedical science initiative that illustrates this de-
fensive deployment is the “care.data” project in the UK.
In 2012, the UK Parliament passed the Health and Social
Care Act (HSCA), which provides for the creation of the
Health and Social Care Information Centre (HSCIC), a cor-
porate body owned by the UK government with the power
to collect, collate and provide access to the medical infor-
mation for all patients treated by the NHS in England,
whether in hospitals or by General Practitioners (GPs). Be-
fore the enactment of the HSCA, patients’ hospital data
had already been collected and made available to re-
searchers and others by the NHS Information Centre (set
up by the Health and Social Care Act 2010), the forerunner
to the HSCIC, and GPs had already started using standar-
dised computerised record-keeping systems, but these re-
cords were not transferred to a central database.
The legal basis for the care.data project ‘trumps’ key
provisions of the Data Protection Act [38]. The 2012 Act
(the HSCA) allows all patient data to be used for purposes
Woolley et al. BMC Medical Ethics  (2016) 17:33 Page 6 of 17
that extend beyond patient care (e.g. for research) without
any consultation, i.e. without the patients’ knowledge.
Thus, the law makes it impossible for patients to prevent
their data from being used for research. Indeed, under the
HSCA physicians are obliged to forward their patients’
medical records to the HSCIC which itself is not obliged
to inform the patient of the use of such data once ‘anon-
ymised.’ [38] 2
The NHS website states that it developed the care.data
programme as an initiative “to ensure that there is more
rounded information available to citizens, patients, clini-
cians, researchers and the people that plan health and
care services,” and “to ensure that the best possible evi-
dence is available to improve the quality of care for all,”
[39]. Benefits of the scheme mentioned include the pos-
sibility for researchers to “identify patterns in disease
and the most effective treatments”; the possibility “to
find more effective ways of preventing or managing ill-
nesses; advise local decision makers how best to meet
the needs of local communities; promote public health
by monitoring risks of disease spread; map out pathways
of care to streamline inefficiencies and reduce waiting
times; determine how to use NHS resources most fairly
and efficiently,” As the healthcare provider for all UK
residents, the NHS possesses an immense quantity of
genotypic and phenotypic data, and has access to mil-
lions of patients’ bodies and tissue samples. Indeed, the
NHS data bank is a potential goldmine for a range of re-
searchers, including for-profit companies seeking to de-
velop drugs or diagnostic tests.
The potential positive impact of the care.data programme
has been acknowledged by various organisations, such as
the Royal College of General Practitioners and the British
Medical Association [40]. However, the scheme has met
with significant opposition. In autumn 2013, NHS England
had set up a care.data website where citizens could record
their concerns. The public response was vocal, and in-
cluded strong concerns about the following: lack of trans-
parency; lack of respect for confidentiality and privacy;
misgivings about the opt-out basis for participation; 3 ero-
sion of trust in GPs and the health care system; wrongful
appropriation of personal property; commercialisation; and
uses of personal health data that conflict with the person’s
moral values. One of the particular bones of contention
was the prospect that commercial companies could have
gained access to patient data through care.data, and that
this was not communicated clearly to patients [41].
The government decided to delay GP data harvesting
until autumn 2014 to allow NHS England the opportunity
to persuade GPs, healthcare workers and patients that the
care.data scheme was valuable and that sufficient safe-
guards had been put in place. It was decided to pilot the
GP data harvesting within a group of ‘pathfinder’ areas in
England, 4 and to initiate a series of public discussion
sessions with the care.data Advisory Group. According to
the most recent update provided by the British Medical
Association: “The purpose of the pathfinder stage is to
trial, test and evaluate the data collection process and
communications to patients,” [42]. As a part of this pilot
stage, the project sponsored 150 “listening events” for
health professionals, patient groups and the public, during
which “more than 3000 people shared their comments
and concerns,” [43]. In announcing these engagement ex-
ercises, Tim Kelsey, then NHS England’s National Director
for Patients and Information, explained that:
Care.data [is] a programme of work which aims to
consistently and systematically use and join up data
across hospitals and general practice and make it
available to the people who can use it to make services
better—clinicians, commissioners, researchers, charities,
patients and public—in safe ways that minimize the
risk to a person’s privacy being compromised in an age
of increasingly sophisticated digital threats…. Data
sharing between professionals, patients and public is the
precondition for a modern, sustainable health and care
service (emphasis added) [44].
Calls for data-sharing between the professionals and
their institutions in health care –the clinicians, commis-
sioners, researchers, charities and, presumably, the com-
mercial concerns dedicated to translating data into
health care products—are nothing new. However, in-
cluding patients and the public amongst those “who can
use [data] to make services better” seems to promise a
level of public engagement that verges on “involvement.”
The architects of the care.data project came to this rhet-
oric primarily in response to a public outcry, however,
and it remains unclear what role it might actually be
promising, given traditional understandings of the trans-
lational research process.
The precision medicine initiative (US)
The framing of our second case study—the US government-
sponsored Precision Medicine Initiative (PMI)—relies on
the popularity of citizen science rhetoric. The PMI was an-
nounced by President Barack Obama in his State of the
Union Address in January 2015 and reinforced by the lead-
ership of Francis Collins, the director of the US National In-
stitutes of Health (NIH), and by the infrastructure and
resources of NIH [45].
The purpose of the PMI is to promote and pursue the
“paradigm shift” that the Human Genome Project
(HGP) promised for healthcare. As the White House
website explains:
Until now, most medical treatments have been
designed for the “average patient,” As a result of this
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“one-size-fits-all” approach, treatments can be very
successful for some patients but not for others.
Precision Medicine, on the other hand, is an innovative
approach that takes into account individual differences
in people’s genes, environments, and lifestyles. It gives
medical professionals the resources they need to target
the specific treatments of the illnesses we encounter,
further develops our scientific and medical research,
and keeps our families healthier [45].
The PMI consists of an infusion of US $215 million into
efforts to accomplish this goal over a “3-4” year period, in-
cluding “ US $130 million to NIH for development of a vol-
untary national research cohort of a million or more
volunteers to propel our understanding of health and dis-
ease and set the foundation for a new way of doing research
through engaged participants and open, responsible data
sharing,” [46]. To accomplish this, Collins, writing with
former director of the National Cancer Institute Harold
Varmus, outlined the potential of precision medicine:
We envisage assembling over time a longitudinal
“cohort” of 1 million or more Americans who have
volunteered to participate in research. Participants will
be asked to give consent for extensive characterization of
biologic specimens (cell populations, proteins,
metabolites, RNA, and DNA — including whole-genome
sequencing, when costs permit) and behavioral data, all
linked to their electronic health records [46, 47].
The government’s strategy has been to invoke the ap-
peal of participant-driven “citizen science” to garner sup-
port for patient participation in the PMI, despite the
irony of appropriating rhetoric intended to promote de-
institutionalizing and “democratizing” scientific research
to increase support for an exercise of Executive Branch
power through the government’s centralized biomedical
research funding agency. As the White House reports:
Participants will be involved in the design of the
Initiative and will have the opportunity to contribute
diverse sources of data—including medical records;
profiles of the patient’s genes, metabolites (chemical
makeup), and microorganisms in and on the body;
environmental and lifestyle data; patient-generated
information; and personal device and sensor data.
Privacy will be rigorously protected. This ambitious
project will leverage existing research and clinical
networks and build on innovative research models
that enable patients to be active participants and
partners (emphasis added) [46].
Since January 2015, a series of workshops and confer-
ences have been held to flesh out this “patient-powered”
vision of the PMI. These meetings have brought together
architects of online crowd-sourced science projects, disease
advocacy groups, and “consumer genomics” companies to
extract lessons about participant-driven research [26].
One of the goals—and challenges—that has emerged in
these conversations is how to create a “culture shift” such
that patients and their families become “the true engines”
of precision medicine [48]. To date, much of the foundation
for this culture shift has been laid by parents whose
children have rare or undiagnosed conditions: “Racing
against the clock to save their children, parents are building
databanks, connecting scientific dots and fueling thera-
peutic advances that could otherwise take a decade or more
to happen,” [48]. As the leader of nonprofit health advocacy
group Genetic Alliance effused, “this is what [we have] been
working towards for years. I am delighted by the President’s
recognition of the power of participants in this initiative.
Together with other advocates, citizen scientists, and re-
search participants, we are thrilled to roll up our sleeves
and get started!” [49].
Isaac Kohane, who is chair of Harvard Medical School’s
Department of Biomedical Informatics and hosted one of
the conferences, similarly heralded the potential of a much
larger culture shift such that patients “feel empowered
morally and intellectually to lead in precision medicine re-
search and delivery.” [48].
NIH also convened a PMI Working Group to develop an
operational recruitment proposal for the PMI-Cohort Pro-
gram of a million participants [27]. When it issued its rec-
ommendations in September 2015, the NIH PMI Working
Group report embraced this culture shift explicitly: “Partici-
pant engagement and empowerment are core values for the
PMI-Cohort Program (PMI-CP). Whereas the majority of
clinical research has been transactional in nature, with uni-
directional data sharing from the individual to the study,
the PMI-CP seeks true partnership between participants
and researchers” (emphasis added) [50].
Building that partnership, the Working Group goes on to
say, relies on better communication with the public so that
individuals understand the significance of research and how
their participation in it brings health benefits for them-
selves, their families, and their communities. A primary
goal of the PMI cohort is therefore to “empower individuals
to understand potential opportunities to manage their
health offered through genomic sequencing, aggregation of
longitudinal health information, and sharing of data with
researchers, under a cooperative model of partnership and
trust … and shared responsibility for health knowledge (em-
phasis added),” The Working Group expects the PMI to
“exemplify engagement at its best,” [50]. The PMI cohort,
as it is built, will require a “substantial variety of data access
and analysis services and support to help researchers of
varying levels of sophistication, including ‘citizen scientists’
and study participants, achieve their research goals.” [50].
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Although the term “citizen science” is not regularly used
in the PMI initiative documents, it is clear that the White
House is actively trying to promote the spirit of “open sci-
ence and innovation,” values that are core to participant-
driven citizen science initiatives [11]. A recent White House
webcast was designed to raise awareness of citizen science
and crowdsourcing tools as “approaches that educate, en-
gage, and empower the public to apply their curiosity and
talents to a wide range of real-world problems,” and ultim-
ately build a science “of the people, by the people, for the
people.” [19]. To this end, Francis Collins wrote:
[T]he Precision Medicine Initiative Cohort Program
will change the way we do research. Participants will be
partners in research, not subjects, and will have access
to a wide range of study results. What we’re doing with
the Precision Medicine Initiative cohort is intersecting
in a synergistic way with other fundamental changes in
medicine and research to empower Americans to live
healthier lives (emphasis added) [51].
In considering the case study of the PMI it is import-
ant to note that this initiative is still unfolding, having
been announced at the beginning of 2015. The ramifica-
tions of utilizing rhetorical appeals to citizen science in
framing opportunities to participate in a national re-
search initiative will need to be traced as recruitment,
enrollment, and involvement of participants into the
PMI-CP gets underway.
Discussion: Ethical and policy implications
It is true that the sociopolitical contexts of care.data and
the Precision Medicine Initiative are not entirely alike.
Dissimilar healthcare systems in the UK and the US can
lead to different views on the role of the government in
the administration of population-based medical research.
For instance, in the UK, where healthcare is seen as a
right afforded to all citizens, it is natural to expect that
government institutions like the NHS will hold health-
related data for the purpose of treating individuals and
populations. It is expected that the government, and not
external third parties, will be responsible for ethical
stewardship of that data. In the US, on the other hand,
where private healthcare is the norm, this is not the
case. Here, private institutions are responsible for stew-
ardship. Government involvement occurs, more often
than not, through regulatory restrictions on how data
should be managed and whether it should be shared be-
yond a given institution. The tenor of the former is more
proactive, the tenor of the latter is more reactive. This
distinction marks a key difference which reverberates
throughout the two case studies. Yet when the connec-
tion between an individual’s data and an individual’s care
is severed so that data is shared or sold with the more
general aim of improving biomedical research, the rela-
tionship between the individual and the institution
trusted with stewardship is significantly altered. In this
way, the two cases are alike. And they each raise norma-
tive questions about the role of government in managing
the interests of the individual and the interests of others
who would benefit from, or stand to profit from, access
to that individual’s data.5
Both the English care.data project and the US Preci-
sion Medicine Initiative are research projects initiated by
national governments to address health care questions
by using biomedical information about their citizens. As
such, these governments put their respective populaces
in the position of being offered for study by academic
scientists, health care institutions, and private industry.
Unlike the national census, neither initiative is critical to
either nation’s ability to govern. Moreover, unlike popu-
lation health surveillance efforts like the US Center for
Disease Control’s “National Health and Nutrition Evalu-
ation Survey,” neither initiative is primarily aimed at
governmental planning for national public health needs. In-
stead, both are aimed at improving the medical interven-
tions that their health care systems can offer patients—by
increasing the amount and variety of biomedical data to
which non-governmental scientists, entrepreneurs, and
commercial entities have access in order to develop new
medical interventions.
The governmental leveraging of such “public/private
partnerships,” allegedly for the benefit of public welfare
and national economies, is not unusual. And, although
both initiatives were conceived and launched by execu-
tive rather than representative branches of government,
they were eventually vetted and authorized by each
country’s political process. However, the roles of the citi-
zenry in each of our case studies are quite different, and
they shed cautionary light on how the popular appeal of
“citizen science” and “public engagement” rhetoric can
be (mis)used in state-sponsored biomedical research,
even in liberal democratic nations.
Many unanswered questions lurk beneath this rhetoric.
Complicating factors include the ways various interests are
represented in government; the ways potentially conflicting
interests collide in mandated data sharing; the influences of
commercial interests over and above individual interests in
policy development; and the inadequate attention given to
the implications of the roles that the citizenry plays. We
discuss each of these in turn.
With respect to the potential for conflicting interests
colliding in mandated data sharing, the U.K. care.data pro-
ject presents itself as a “data-sharing” project rather than a
“citizen science” or “public engagement” project per se.
“Data-sharing” is a label that typically describes a profes-
sional transaction between scientists—the practice of
pooling or combining data from separate investigations to
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provide a more robust foundation for research—and has
gained wide appeal within the scientific community over
the last two decades as an antidote to an increasingly
competitive and secretive research environment credited
to the advent of commercial interests in the life sciences
[52]. In that context, “data sharing” in science resonates
well with the appeal of “open source” software develop-
ment and collective “crowdsourced” resources like
Wikipedia. Initially, this provided a persuasive platform
for the launch of care.data, from which its proponents
could argue that the NHS’s individual patient confidential-
ity concerns impeded progress [53].
Contemporary science policy emphasizes the need to
use “technology transfer” from the public to the private
sector to translate basic science “from the bench to the
bedside,” Most data-sharing initiatives, including care.-
data, are as much about speeding the commercialization
of research findings as they are about open communica-
tion between clinicians and/or scientists. It is a case of the
asymmetric influence of commercial interests over and
above individual interests in policy development. Indeed,
the prospect of (re)identifiable personal medical informa-
tion flowing from the NHS into the private sector without
patient permission is what provoked the groundswell of
public concern that has delayed the initiative and the
eruption of “public and patient engagement” rhetoric to
show how “NHS is committed to listening to and working
with professionals and patients to gather their feedback on
how to implement care.data.” [53, 54].
Expanding the circle of “the people who can use
[shared Electronic Medical Records data] to make ser-
vices better” to include patients and the public, and cit-
ing their involvement in data-sharing as a “precondition
for a modern, sustainable, health and care service,” [44]
could be read as a remarkable commitment of NHS to
the democratization of biomedical research and public
empowerment, very much in the spirit of “citizen sci-
ence” in its robust sense. It suggests that patients and
the public will have direct access to the data collected
through the care.data project and be given roles in the
research process.
Or does it? Despite this rhetoric, the care.data project’s
rules are vague on what kinds of third parties may pur-
chase access to the data, and it is not clear whether the
project’s “listening events” have had any impact on its
scientific design or research mission. Instead, what the
NHS seems to mean by “data sharing between profes-
sionals, patients and the public” as a fundamental pre-
condition for its service is simply “data sharing between
professionals,” ideally with patient and public under-
standing. “Informational altruism” may be a modern day
civic virtue, but until we reach the point at which med-
ical confidentiality endangers the social fabric, a willing-
ness to share one’s self with the world remains a virtue
to be praised rather than encouraged through insinua-
tions of co-ownership and control.
These attempts to engage the public do not draw from
policy frameworks that support normative analysis of the
role of citizenry in new and emerging forms of governance.
Rather, care.data provides an example of a governmental
initiative, in response to public reactions, defensively back-
ing into public engagement rhetoric. What began as a “so-
cial license” to gather and curate health data begins to turn
into a claim about good citizenship [41]. In underscoring
the public’s civic duty to participate in biomedical research,
[55] it tries to provide a strong enough justification for the
conscription of private medical information and its dissem-
ination outside of the national health care system.
Concerns from professional medical bodies and citi-
zens about the implementation of care.data illustrate the
challenges of finding balance between aiming to improve
the quality of care and health services (and stimulate re-
search) on one hand, and respecting ethical values such
as trust, autonomy, transparency, and confidentiality and
privacy on the other. The general public is generally
positive towards medical research and is usually willing
to participate without expecting any personal benefit
[56, 57]. People are less willing to participate, however, if
the benefits to society are unclear or if private profits
might be derived [58]. In order to merit and garner trust,
guardians of citizens’ health data ought to ensure that
they respect the values of the people who are expected
to trust them with their data. Citizens should not have
any fear that they are being manipulated into sharing
their health data.
In the US, the PMI has been explicit in its appeal to
populist rhetoric from its inception. One question this
leads to is whether its appeals are any more substantive
than those of care.data. If the PMI is sincere about giv-
ing its participants a substantive role as “partners” in its
investigations, a second question follows: What should
we make of that from an ethical perspective? For ex-
ample, does it make a difference ethically whether the
public participants are merely data collection assistants
or genuine “co-investigators”?
The vast majority of the PMI samples and data will be
gathered through participating biobanks and health care
organizations, which will add a layer of communication
complexities and informational barriers between indi-
vidual sources and the PMI-CP at NIH. Even with expli-
cit “opt-in” procedures in place for patients and biobank
contributors, it is not clear whether these participants
will have any more direct engagement with the PMI
than the patients whose medical records are opened in
the care.data initiative. With proposed changes to the
US human subjects research regulations, [59] patients
could “consent” to their sample and data donations as
routine paperwork upon admission to the hospital, and
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be justifiably surprised when their first PMI participant
newsletter arrives in their (e)mail.
At the same time, for those who proactively enroll as
“participants at large,” it does seem clear that the PMI
would like to take advantage of the growing interest in
personal health monitoring to enlist their services as data
collectors for the PMI and its scientific and commercial
clients [50]. In this sense, the PMI displays the same weak
form of “citizen science” celebrated by other governmental
and institutional initiatives that enlist members of the
public to collect and report empirical observations, such
as the UK’s OPAL projects [60]. As (unpaid) scientific
field-workers, participants are invited to donate their
health monitoring time and energy to the initiative and, in
return, are promised regular reports of the initiative’s pro-
gress. Unlike citizen science projects in astronomy, orni-
thology, or ecology, which depend on the assistance of
engaged members of the public, the PMI instead promises
tangible “translational” benefits that could be shared: both
health benefits for families suffering from rare or recalci-
trant diseases, and financial profits to be made by turning
its findings into medical innovations. Both of these forms
of translational benefits raise the stakes of contributions
to the PMI enough to make the participants’ informational
altruism look less like laudable civic volunteerism and
more like the exploitation of the gullible.
The partnership rhetoric of the PMI, however, does
seem to offer a more substantive role for its public partici-
pants. But what could that role be? There is little chance
that participants will be encouraged to conduct “DIY gen-
omics” studies of their own using the PMI’s platform, or
that “the ingenuity of the American people” will be har-
nessed through “crowdsourcing” to solve scientific puz-
zles. Despite its references to personal empowerment and
the interests of rare disease advocacy groups in organizing
their own research efforts for the benefit of their constitu-
encies, the PMI is not proposing to make citizens scien-
tific co-authors of its research in either literal or figurative
ways. At the same time, the PMI does seem to offer its
participants some role in the governance of the initiative.
Perhaps this is the sense in which it aspires to rise to the
level of “citizen-led” science.
The implementation plans for the PMI are still being
developed, so it is difficult to discern how the project’s
projected one million biospecimen and data donors will
be meaningfully engaged as “partners.” The donors who
will make up the bulk of the collection are unlikely to be
actively engaged in design and management because its
infrastructure and processes will need to be in place be-
fore they are recruited. It is possible that the PMI’s pub-
lic “participants at large” will be more motivated to be
engaged, but how their voices will be heard is unclear,
short of recreating a democratic system of elections
from within the cohort for representation on the PMI’s
governing committees. Already, some of the constituen-
cies that might naturally represent segments of the co-
hort, like advocacy groups and charities, have been cut
out of the governance system in a move to avoid the in-
fluence of “special interests,” [50].
The populist rhetoric of the PMI is clearly at least in part
a strategic effort to increase public participation and sup-
port. Governmental agencies and Big Science projects need
ever-larger numbers of people to pursue their population
genomic goals, and they are happy to trade on the ideals of
solidarity and volunteerism that accompany “citizen sci-
ence” to meet those needs. As such, populist rhetoric ap-
peals to the rising public interest in participant-driven
disease advocacy research and citizen science contexts,
which is also often accompanied by frustration with the
bureaucratic constraints of the research regulatory process
[11]. Ironically, in the PMI context, the reforms that propo-
nents advocate are not designed to deinstitutionalize re-
search or make it easier for lay people to control. Instead,
they are aimed at making it easier for research institutions
to advance the movement’s medical and political goals by
diluting and dismantling conventional individual informed
consent requirements. Such a top-down approach to citizen
science runs the risk of watering down the role of the citi-
zen research subjects in the PMI’s “genomic research par-
ticipant corps” to passive sources of data [11].
Perhaps in recognition of this potential, advocates of
the PMI are anxious to expose and address the problem
that the biomedical research regulatory system in the US
is not set up to facilitate de-institutionalized “citizen sci-
ence” efforts. As Collins and Varmus advocate in their
manifesto for the PMI:
Achieving the goals of precision medicine will also
require advancing the nation’s regulatory frameworks.
To unleash the power of people to participate in
research in innovative ways, the NIH is working with
the Department of Health and Human Services to
bring the Common Rule, a decades-old rule originally
designed to protect research participants, more in line
with participants’ desire to be active partners in
modern science [47].
In this regard, it is telling that, despite its invocation of
the populist appeal of “bottom up” citizen science, the
White House uses a naval metaphor to promote the PMI,
urging that: “[t]ranslating these successes to a larger scale
will require a national effort: to push this effort forward we
will need all hands on deck, including patients, hospitals,
industry,” [61] This suggests that members of the public,
and the research institutions with which they interact, are
part of one national crew, susceptible of being called to
duty as required by the needs of the ship of state. Taken to
its logical conclusion, this line of thinking could even be
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used to support an expectation that every citizen become
engaged in precision medicine research, as a matter of col-
lective duty, running the risk of re-inscribing prejudicial as-
cribed identities with the very scientific tools that could be
used to bring us past them to a real “paradigm shift” for
biomedicine, and the use of those identities to unfairly in-
fluence participation in research and public health interven-
tions [62].
The traditional, localized, case-specific contexts around
which much policy development formed over the past
50 years has not prepared us for the regulatory challenges
we now face. Biomedical research has been based upon a
model of altruistic gift giving of sample and data to gener-
ate knowledge in the service of promoting the greater good
of society. But now that model is being used to support an
entirely different research edifice, which elicits entirely dif-
ferent normative concerns. The term “partnership” is mis-
representative. It masks a complex state of affairs in which
the aggregation of diverse interests that result from data
sharing is met with an uncomfortable (and greater) influ-
ence of government. This asymmetry raises the specter of
governmental and commercial interests that impinge on in-
dividual rights, and renders nominal at best any claims of
advancing societal good. What is to keep a self-serving
model of industry from destroying the public trust and
good faith that the biomedical community has cultivated
over the past half century? Even if a vast majority of com-
mercial interests maintain a significant convergence with
the good of society, it does not take many bad actors to poi-
son the well.
The concept of “partnership” implies not only co-
leadership but co-ownership, with an equitable share in
a collaborative venture’s returns. Promising that the PMI
will rise to the level of a co-production between the
PMI-CP, its scientific and commercial clients, and its
public participants suggests that those participants might
reasonably see their contributions not as altruistic dona-
tions but as investments—and expect to reap tangible
dividends, either in terms of health care benefits or fi-
nancial profits. Inevitably, this sense of public solidarity
that the PMI seeks to cultivate evaporates under the
pressure of this logic, as groups of participants find com-
mon ground in trying to influence the initiative’s govern-
ance to prioritize their own special interests.
Ironically, the UK and the US already struggle with this
same issues of engagement, involvement, and participation
in their efforts to mount international genomic research
collaborations like the “H3 Africa” initiative. Just as the
nations participating in those efforts seek to protect their
own interests by declaring “genomic sovereignty” over
their populations’ biospecimens and data, it will be rea-
sonable for families (like the descendants of Henrietta
Lacks) to seek to protect their “genetic legacies” from ex-
ploitation, rare disease groups (like PXE Int’l) to secure
patent protections in the commercialization of “their
genes,” and communities (like the Havasupai tribe) [63] to
demand control over the questions scientists might pursue
using “their people’s” samples [64].
Conclusion: taking “citizen” seriously
In considering the policy implications of our analysis, it
is helpful to return to the phrase “citizen science,” The
current facile use of “citizen” in “citizen science” in the
biomedical community conceals a real need. If the term
“citizen science” is to be widely used, policy concerning
it needs to be in tune with the normative realities of bio-
medical data sharing. In employing the term “citizen,”
“citizen science” initiatives fuse the languages of bioeth-
ics and governance. Consequently, in addition to raising
questions concerning ethical oversight of medical re-
search, they also raise questions concerning just partici-
pation and engagement. They call into question what
the reciprocal relationship between and individual and
society ought to be. This question has been a focus of
bioethicists who have called for a new social contract be-
tween individuals and society that can better support
biomedical research [65–69]. There is disagreement
about what a new social contact should include. But,
nevertheless, a model of participation and engagement
which draws on the idea of a social contract would allow
one to more readily think beyond current models, such
as the altruistic and profit-oriented ones discussed
above, which can easily conflict. It would allow one to
think more directly about what being a citizen in a just
society means.
It is clear that many who use the term “citizen science”
have quite different views of what the term “citizen”
means. This has ramifications for their views on what “so-
cietal good” means, on individual rights and duties, and
on what authority governments should possess. Each per-
spective therefore carries with it its own set of normative
assumptions and consequences. At its most immediate
level, the use of the word “citizen” lays emphasis on the
relationship between individuals and the societies within
which they live. It naturally raises the question: What is
the relationship between citizen responsibilities and gov-
ernment regulations when viewed against the societal
good that biomedical sciences promises to provide? While
the question is simple, the answer is, of course, compli-
cated. However, some points are less contestable than
others. For instance, in democratic societies, it is not too
controversial to say that “citizen” is inextricably linked to
some form of self-determination; autonomy helps justify a
government’s authority. Citizens may thereby hold the
protection of autonomy sacrosanct.
In government led initiatives like care.data and PMI
we face more than the perennial bioethical challenge of
balancing the greater good with individual rights. Above,
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we mentioned Prainsack’s typology as one way to better
understand competing visions of societal good by determin-
ing whether and how a given citizen science initiative
makes science more socially robust by corresponding with
commonly shared values. In democratic societies, the pres-
ervation of autonomy is one of those commonly shared
values. Therefore, if a citizen science initiative is to be por-
trayed as both socially robust and as advancing societal
good in a democratic society, public participation cannot be
decoupled from the process that determines the vision for
society being pursued. Further, as autonomy is also a pri-
mary principle of bioethics and related law, there is an es-
sential nexus of normative principles that span both
governance and bioethics such that individual interests
need to be respected and harmonized along the lines of
sound, clearly articulated, principles which present a coher-
ent vision of the rights and duties of, not just citizens, but
of all actors. In the context of biomedical research, auton-
omy is most directly expressed by the giving of consent. In
this sense, a strong connection can be drawn between the
roles of consent in political theory, in bioethics, and in the
pursuit of societal good in democratic societies. 6
As we have seen, in citizen science contexts, ICT offers
new models of data collection, processing and analysis, and
thus new kinds of opportunities for engagement in these
aspects of research. One of the key support mechanisms
for participation is the consent process. Depending on the
participatory model and the specific research project, the
expectations of the role of the participant can lead to vari-
ation in the approach to consent. Such variation can be a
challenge for policy development. Yet, ICT also present
new opportunities for governance of research, specifically
for consent, which help to address this challenge. For ex-
ample, dynamic consent [70] is being explored as an oppor-
tunity for participants to have greater, more nuanced
control over their participation in research by being able to
determine how their data are used, and even to change
their mind as research progresses. It could also be used as a
tool during research, to update participants on the progress
of research [71]. This could greatly encourage participation
and engagement. Some consider the use of interactive in-
formation technology like these that engage and communi-
cate with participants as central to advancing PCIs [70].
Such a tool would transform the role of the participant in
“citizen science” initiatives, and ensure that the giving of
consent remains linked to concepts of citizenry. 7
Hence, when the term “citizen” is taken seriously, we
can better consider the various contexts within which
“citizen science” is used and the ethical significance of
differences in its uses. This enables us to better see what
vison of societal good is being advanced by the research,
and what other visions are, perhaps, being sidelined by
it. This allows us to be more cognizant of which ethical
ideals are characteristics of which initiatives. It allows us
to see specifically why the ideals of one initiative are not
necessarily compatible with those of others. We then
can better appreciate the problems created for and by
researchers and policymakers when these differing ideals
are represented by a single term, which wrongly suggests
a common ethos.
It is therefore imperative to make visible and clear the
full spectrum of meanings of “citizen science,” the con-
texts in which it is used, and its demands with respect to
participation, engagement, and governance. For instance,
in the examples discussed above, the principle of auton-
omy is approached quite differently. In care.data, whether
the government should have the power to conscript its cit-
izens for their data becomes an important question. But in
participant-centric research initiatives, empowerment of
the individual is central. The balance struck between indi-
vidual autonomy and a greater societal good is different in
each case.
Similarly, the relationship between the citizen and the
powers of government is conceived quite differently in
citizen science initiatives that tout antiregulatory ideals
compared to those that seek to create regulatory infra-
structure. The very idea of “governance” is polarizing.
Differences like these are fairly obvious. But the fact that
they can all potentially be billed as “citizen science,” with
no reference to what “citizen” means or what normative
principles are involved, muddles communication.
As was made evident in the discussion above, broach-
ing this topic promises to create veritable storm of con-
troversy and debate on the very things that facile,
uncritical usage of “citizen science” fails to address. The
eye of this storm is the changing requirements for con-
sent and, by extension, the changing contexts in which
the principle of autonomy is to be applied, or not, as
governance develops. As such, it provides a natural focal
point for deliberation.
There is, of course, already ample debate on what the
role of consent should be in the many contexts of bio-
medical research. But these are largely framed within, or
in reaction to, existing bioethical or policy frameworks
and oversight mechanisms. The approach proposed here
is different. Explicating the varied meanings and uses of
“citizen” will in each case also eventually reveal what
role is envisioned for participation and engagement.
Thus we can articulate more precisely what distinguishes
one “citizen science” initiative from another specifically
in terms of principles of governance.
In thinking holistically about participation, engage-
ment and governance, one can further consider what
bearing each “citizen science” initiative has on a citizen’s
rights and duties, on definitions of “societal good,” on
the powers of government, and on which interests
should hold sway over others. Disambiguating what “citi-
zen science” means along these parameters, one can
Woolley et al. BMC Medical Ethics  (2016) 17:33 Page 13 of 17
more methodically consider what among these many el-
ements gets priority, what gets minimized, and why—in
other words, one can articulate what one thinks the new
social contract should be. This new framing allow us to
cut through the layers of complications discussed above:
the ways various interests are represented in govern-
ment; the ways potentially conflicting interests collide in
mandated data sharing; and the asymmetric influences
of commercial interests over and above individual inter-
ests in policy development. Ultimately, as attempts are
made to engage the public, this modelling will help to
address the disconnect that occurs between government
and the citizenry—by providing a policy framework that
allows for normative analysis of the role of citizenry in
new and emerging forms of governance.
Summary
In this paper, we explored ethical and social implications
of strategies that contemporary national research initia-
tives employ to encourage public cooperation. We began
with an analysis of the mixed uses of “participation,” “en-
gagement,” and “involvement,” and how they pertain to
“citizen science.” And we showed that the multiply ways
“citizen science” is used creates scenarios where scientific
goals, education goals, and financial goals vie for priority.
We then examined a recent turn to inflect biomedical
research with “citizen science” aspirations, suggesting
participants may have deeper investments in research.
Noting the significant confusion that already exists over
the ways the terms “participation,” “involvement” and
“engagement” are used, we argued general citizen sci-
ence rhetoric poses even a greater risk for confusion.
Confusion over different levels of citizen involvement
can be particularly consequential when the rhetoric and
practices of citizen engagement are used by national sci-
ence initiatives that address health care questions by
using biomedical information about their own citizens.
We looked at two such initiatives, the UK care.data and
the US Precision Medicine Initiative.The architects of
the care.data project came to this rhetoric primarily in
response to a public outcry. It remains unclear what role
it might actually be promising to UK citizens. The fram-
ing of PMI relies on the popularity of citizen science
rhetoric, and yet the type of “partnership” is proposes
with participants is still uncertain.
We argue that neither of these initiatives draw from pol-
icy frameworks that support normative analysis of the role
of citizenry. We conclude it is imperative to make visible
and clear the full spectrum of meanings of “citizen science,”
the contexts in which it is used, and its demands with re-
spect to participation, engagement, and governance. In
thinking holistically about participation, engagement and
governance, one can consider what bearing each “citizen
science” initiative has on a citizen’s rights and duties, on
definitions of “societal good,” on the powers of government,
and on which interests should hold sway over others.
Endnotes
1For discussion on strategies an language used by
commercial firms, see [31]. For an analysis of 23andMe
using Prainsack’s typology (discussed above), see [12].
2In fact, HSCIC will not ‘anonymise’ any data; they will
be coded or ‘pseudonymised.’
3It is clear from the public response that an opt-out basis
for such a project is regarded as disrespectful to the citi-
zens. However, as one of the present authors has explained
elsewhere, the care.data project is not even based on an
opt-out model but amounts to conscription. See [72].
4Apparently, in the ‘pathfinder’ areas ‘there will be lots
of activity: local media work, and a new set of communi-
cation materials, including a letter sent by name to every
patient, will be used to raise awareness of the
programme and support GPs prior to a period of data
extraction in those areas only in early 2015. ’ [73].
5Ana Gross argues the disentangling of privacy and
human agency through informed consent and anonymi-
zation initiates a process through which emerges a spe-
cific set of property rights. Research ethics itself thereby
enables “the conversion of privacy into property.” When
interpreted in this way, citizen science initiatives which
seek to decouple the individual from his or her data to
realize its value can be seen as embodying a similar
ethos. In the case of government sponsored initiatives,
one would have to consider the compatibility of this
ethos with principles of governance [74].
6John Rawls is one prominent example in political theory
[75]. Onora O’Neil, an example in bioethics, draws heavily
on autonomy as a principle, distinguishing it from individu-
alism, and thereby establishes one possible way to think
about individual interests and societal good where auton-
omy remains central to the thinking on governance even
when informed consent is not feasible [76]. See also [77].
7This mechanism to improve participation, or to alter
the different elements of participation, and ultimately to
change the role of the participant, has implications for
the different types of citizen science project.
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